Immunofoco’s IMC008 Earns Orphan Drug Designation for Pancreatic Cancer from FDA
Suzhou-based cell therapy developer Immunofoco has announced that it has received orphan drug designation (ODD)...
Drug
Shanghai Haihe Pharmaceutical’s Glumetinib Filed for Marketing in Japan for NSCLC Treatment
Shanghai Haihe Pharmaceutical Co., Ltd has announced the filing for marketing approval in Japan for...
Luye Pharma’s Botawei Receives NMPA Approval for Breast Cancer Treatment
Luye Pharma Group (HKG: 2186) has announced that it has received market approval from the...
Janssen’s Rybrevant Combo Meets Primary Endpoint in Advanced NSCLC Study
Janssen, a subsidiary of Johnson & Johnson (J&J; NYSE: JNJ), has released an update on...
Henan Zhongshuai’s Dexmethylphenidate Hydrochloride Capsules Target Priority Review for Pediatric ADHD
Henan Zhongshuai Pharmaceutical Co., Ltd., a China-based pharmaceutical company, is poised to secure priority review...
Amneal Pharmaceuticals Receives China Approval for Sevelamer Carbonate
US-based Amneal Pharmaceuticals Inc. (NYSE: AMRX) has announced that it has received approval from the...
CSPC Pharmaceutical’s Narlumosbart Approved by NMPA for Bone Giant Cell Tumors
CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its subsidiary, Shanghai JMT Biotechnology Co.,...
Jiangsu Hengrui’s HER2-Targeted ADC SHR-A1811 Aims for CDE’s BTD Status
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced that its HER2 targeted antibody-drug...
Genentech Files for FDA Approval of Crovalimab for PNH, Challenging Soliris
Swiss pharmaceutical giant Roche’s subsidiary, Genentech (SWX: ROG), has submitted its anti-C5 investigational drug, crovalimab,...
Hainan Haiyao Concludes Phase I Clinical Study for PaiEnJiaBin, a Novel KCNQ Agonist
China-based Hainan Haiyao Co., Ltd (SHE: 000566) has announced the conclusion of Phase I clinical...
Brii Biosciences Announces Positive Interim Data for BRII-179 Vaccine in Chronic Hepatitis B
China-based Brii Biosciences Ltd (HKG: 2137) has announced topline cohort-level unblinded Week 36 data from...
MSD’s Gardasil 9 HPV Vaccine Demonstrates 10-Year Efficacy in Adolescents
Merck, Sharp & Dohme (MSD; NYSE: MRK) has released long-term effectiveness data for its recombinant...
Neurophth Biotechnology’s NFS-05 Gene Therapy Gets Australian Clinical Trial Approval for ADOA
China-based gene therapy specialist Neurophth Biotechnology Ltd has announced that it has received clinical trial...
Harbin Gloria Pharmaceuticals’ Zimberelimab Receives NMPA Approval for Cervical Cancer Treatment
China-based Harbin Gloria Pharmaceuticals Co., Ltd (SHE: 002437) has announced that it has received market...
Seagen and Genmab Announce Positive Phase III Results for Tivdak in Cervical Cancer
Seagen (NASDAQ: SGEN), currently in the process of being acquired by Pfizer (NYSE: PFE), and...
SinoMab BioScience’s Suciraslimab Files for Market Approval in China for Rheumatoid Arthritis
Hong Kong-based biotech company SinoMab BioScience Ltd (HKG: 3681) has announced that a market approval...
Columbia University Study Weighs Cost-Effectiveness of Weight-Loss Treatments for Adolescents
Researchers at US Columbia University have published the results of a study estimating the cost-effectiveness...
BDgene Technology Announces Clinical Milestone for CRISPR-Cas9 Gene Therapy in HSK
Gene therapy specialist Shanghai BDgene Technology Co., Ltd has announced the conclusion of three clinical...
Sihuan Pharmaceutical’s Birociclib NDA Accepted for Review by China’s NMPA
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced that the National Medical Products...
Jointown Medical’s COVID-19 Drug Candidate SHEN211 Accepted for Review by NMPA
China-based Jointown Medical Devices Group Co., Ltd (SHA: 600998) has announced that its clinical trial...